diseases
Lev Pharmaceuticals Inc. (LEVP.OB) Granted Authorization to File for European Distribution Rights for Lead Drug Candidate
Read the full article: http://blog.qualitystocks.net/?p=10898
The company announced a letter of agreement with the Sanquin Blood Supply Foundation, which gives Lev the OK to file for European marketing authorization of C1 to treat the life-threatening attacks associated with HAE, such as inflammation of the larynx, abdomen, face, extremities and urogenital tract.
- Login or register to post comments
- Read more
- Email this page
AVANIR Pharmaceuticals (AVNR) Receives European Patent Approval for Extended Commercial Exclusivity for Zenair
Read the full article: http://blog.qualitystocks.net/?p=10709
AVANIR Pharmaceuticals (AVNR) announced the European patent office has granted the company a new patent, which extends the exclusivity period for its lead product candidate, Zenvia - used in the treatment of pseudobulbar affect (PBA) - through 2023.
Vested Interest:
The author does not own shares in AVNR- Login or register to post comments
- Read more
- Email this page
Related Articles
- AVANIR Pharmaceuticals (AVNR) Receives European Patent Approval for Extended Commercial Exclusivity for Zenair
- Lev Pharmaceuticals Inc. (LEVP.OB) Granted Authorization to File for European Distribution Rights for Lead Drug Candidate
- GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
- China Pharma Holdings Inc. (CPHI.OB) Posts Positive Q3 Results Across the Board
- BioScrip (BIOS) Quarterly Revenue and Net Income Soars